Hutchmed China hails lung cancer trial results published in Lancet
(Alliance News) - Hutchmed China Ltd on Wednesday said the results from its SACHI phase-three lung cancer trial have been published in medical journal the Lancet. Read More
| Price | 226.00p on 15-01-2026 at 19:40:07 |
|---|---|
| Change | 16.00p 7.62% |
| Buy | 230.00p |
| Sell | 225.00p |
| Last Trade: | Buy 7,551.00 at 226.00p |
| Day's Volume: | 42,581 |
| Last Close: | 226.00p |
| Open: | 225.00p |
| ISIN: | KYG4672N1198 |
| Day's Range | 220.00p - 228.00p |
| 52wk Range: | 187.50p - 292.00p |
| Market Capitalisation: | £1.94b |
| VWAP: | 224.25602p |
| Shares in Issue: | 859.52m |
Sector: Medicine and Biotech
Listed In: FTSE AIM 100, FTSE AIM All-Share,
Hutchmed (HCM) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 7,551 | 226.00p | Suspected BUY Trade |
16:35:27 - 15-Jan-26 |
| Buy* | 2,557 | 225.00p | Automatic Execution |
15:28:57 - 15-Jan-26 |
| Sell* | 1,116 | 225.00p | Automatic Execution |
15:28:57 - 15-Jan-26 |
| Sell* | 1,119 | 225.00p | Automatic Execution |
15:28:57 - 15-Jan-26 |
| Sell* | 92 | 225.00p | SI Trade |
15:28:11 - 15-Jan-26 |
| Sell* | 56 | 225.377p | Negotiated Trade |
15:17:18 - 15-Jan-26 |
| Sell* | 1,331 | 225.548p | Negotiated Trade |
14:54:41 - 15-Jan-26 |
| Sell* | 2,000 | 225.12p | Ordinary |
14:53:17 - 15-Jan-26 |
| Sell* | 2,690 | 225.12p | Ordinary |
14:45:57 - 15-Jan-26 |
| Unknown* | 0 | 224.00p | SI Trade |
14:37:32 - 15-Jan-26 |
Hutchmed (HCM) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 14th Jan 2026 7:00 am | RNS-R | Publication of Phase III Results in The Lancet |
| 7th Jan 2026 7:00 am | RNS-R | Positive Topline Results of Phase III Trial |
| 5th Jan 2026 7:00 am | RNS-R | Surufatinib + Camrelizumab PDAC Phase 3 initiation |
| 31st Dec 2025 7:00 am | RNS | Total Voting Rights |
| 31st Dec 2025 7:00 am | RNS | Total Voting Rights |
| 30th Dec 2025 10:00 am | RNS-R | China NDA Acceptance-Savolitinib in Gastric Cancer |
| 30th Dec 2025 10:00 am | RNS-R | China NDA Acceptance-Savolitinib in Gastric Cancer |
| 29th Dec 2025 8:30 am | RNS | Blocklisting Six Monthly Return |
| 29th Dec 2025 8:30 am | RNS-R | NDA Acceptance in China for Fanregratinib |
| 29th Dec 2025 8:30 am | RNS-R | NDA Acceptance in China for Fanregratinib |